granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

, e.g., supermarket, food and restaurants (only for takeaway), drug stores.  Online sales continued to grow remarkably by 150.0% YoY.  Gross profit margin from sale of goods improved outstandingly to

TRIPPLE LIFT SERUM 2. SOS HYALURON X3 CONCENTRATE SERUM 3. SOS HYALURON & COLLAGEN FREEZE-DRIED MASK 4. OXE’CURE ACNE CLEAR POTION 5. OXE'CURE ACNE CLEAR POWDER MUD 6. OXE’CURE ACNE CLEAR POWDER LOTION 7

and Clause 5 or Clause 6, as the case may be; (d) having a plan to report the results of the experiment and progress of service provision to the SEC Office on a continuous basis; (e) having a clear exit

, as the case may be; 2 (d) having a plan to report the results of the experiment and progress of service provision to the SEC Office on a continuous basis; (e) having a clear exit strategy in case of

business. The company is able to maintain current customers, nevertheless, the plan is to clear out all of the remaining Inventory as soon as possible. The company, therefore, has initiated a contract

accordance with the 2 following principles: (1) good governance and clear, transparent organizational structure; (2) effective risk management for legal, credit, liquidity, operation, and other risks, with

fast changing and hard-to-predict landscape, policy implementation must be timely and effective, and a key to achieve tangible results is to implement clear and efficient action plans with cooperation

Conversion Scheme, the Company will be able to clear a total debt of USD 219,277,709 (divided into the Net Trade Debt to be converted into equity of USD 123,899,729 and the 1st Interest Portion to be waived of